Scopus (CiteScore 2022 =3.0, Q3) , ISC
RE: The review of your title for Scopus is complete
 
Scopus Title Evaluation Support <[email protected]>
To:sami sajjadifar
Cc:Zeinab Arzehgar
 
Thu, Feb 24, 2022 at 9:15 AM
 
 

Dear Dr. Dr. Sami Sajjadifar,

 

Re: Eurasian Chemical Communications  ( 2717-0535 / 2676-6280 )

Thank you for your e-mail. As mentioned in the below acceptance e-mail:

If Scopus already has a license agreement in place with your organization for content access, no further action is needed from your end at this point.

If we do not have a license agreement in place, and you are the journal editor or publisher, your Engagement Manager will reach out to you in the next three months to discuss next steps on the content access set-up. Your Engagement Manager’s role is to guide your through the Scopus onboarding process and ensure that everything runs smoothly. You can learn more about the onboarding process in the Scopus Content Provider FAQ.

In general, all recently accepted titles will be listed separately in the Scopus Title list within 1 month after acceptance, see the second tab 'Accepted titles'. If you can't find your title there, please check the tab 'Scopus sources'.

 

With kind regards,

 

Karin Jongeneelen

Scopus Title Evaluation Specialist ELSEVIER BV

=================================================================================================
On Tuesday, February 22, 2022, 08:16:08 AM GMT+3:30, Scopus Title Evaluation Team <[email protected]> wrote:
 
 
Title: Eurasian Chemical Communications
ISSN / E-ISSN: 2717-0535 / 2676-6280
Publisher: Sami Publishing Co-Spc

Dear Zeinab Arzehgar,

Congratulations, your Eurasian Chemical Communications has been accepted for Scopus.

The Scopus Content Selection & Advisory Board (CSAB) has reviewed your application and approved it for coverage.

For your information, the reviewer comments are copied below:

The performance of the journal, in terms of its citedness, marginally fulfills the criteria for inclusion in Scopus. The editors are advised to invite editorial board members and active researchers from the international scientific community to contribute articles to enhance the citedness and the impact of the journal. Scopus will monitor the performance of this title for re-evaluation in due course.

What’s Next?

If Scopus already has a license agreement in place with your organization for content access, no further action is needed from your end at this point.
If we do not have a license agreement in place, and you are the journal editor or publisher, your Engagement Manager will reach out to you in the next three months to discuss next steps on the content access set-up. Your Engagement Manager’s role is to guide your through the Scopus onboarding process and ensure that everything runs smoothly. You can learn more about the onboarding process in the Scopus Content Provider FAQ

In general, all recently accepted titles will be listed separately in the Scopus Title list within 1 month after acceptance, see the second tab 'Accepted titles'. If you can't find your title there, please check the tab 'Scopus sources'.


Yours sincerely,


Scopus Title Evaluation Support



___________________________________________________________________

Notice: Scopus is owned by Elsevier B.V. and Elsevier is solely responsible for the content selection policy of Scopus. In order to come to a decision to accept or reject a title for Scopus, Elsevier follows the independent advice from the Scopus Content Selection & Advisory Board (CSAB). However, Elsevier and the CSAB reserve the right to change decisions, adjust the selection criteria, or re-evaluate titles that are accepted for Scopus without prior notice. Decisions made by the CSAB do not guarantee inclusion into Scopus due to not being able to come to terms with the publisher on a licensing agreement. In no event shall Elsevier be liable for any indirect, incidental, special, consequential or punitive damages arising out of or in connection with any advice disclosed or any selection decision made. This statement must not be used for advertisement purposes.